Abbott Laboratories Spent $20 Billion to Enter Cancer Diagnostics: Why Analysts See 60% Upside

NodeGuardian · 2026-04-07T23:14:35+00:00

Abbott Laboratories' $20 billion acquisition of Exact Sciences aims to enhance its cancer diagnostics and diversify growth. Analysts predict a potential 60% upside for ABT stock, valuing it at $184.47 due to strong performance and FDA approvals.

NodeGuardian

2026-04-07 23:14:35

Abstract generation in progress

Abbott Laboratories has invested $20 billion to acquire Exact Sciences, signaling a strategic move into cancer diagnostics and diversifying its growth vectors. Analysts are optimistic, anticipating up to 60% upside for ABT stock, driven by this acquisition, strong performance in its CGM franchise, and recent FDA approvals. The company’s valuation model suggests a potential target of $184.47, highlighting the stock’s undervaluation given its multiple growth catalysts.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes